Archive for the ‘Lyme’ Category

Lyme Disease Patient Got Worse on Antibiotics – Until We Adjusted the Dose

https://danielcameronmd.com/lyme-disease-antibiotics/

My Lyme Disease Patient Got Worse on Antibiotics—Until We Adjusted the Dose

He was ready to quit treatment.

The antibiotics were making him feel worse, not better—nausea, fatigue, and a sense that his body was shutting down. He told me, “Doc, I don’t think I can keep doing this.”

I knew we needed a new approach—but not necessarily a new medication. Instead, I asked:
What if we adjusted the dose?


⚖️ When Less Is More

Instead of the standard full dose, we lowered it—just enough to reduce the burden on his system, while still targeting the infection. It was a small tweak, but the impact was big:

  1. His side effects eased within days
  2. His energy improved
  3. And most importantly, his Lyme symptoms began to resolve

🧩 Why Individualized Treatment Matters

This case reminded me that Lyme disease treatment isn’t about pushing patients to the edge—it’s about meeting them where they are. If a full dose overwhelms the system, patients can’t heal. But the right adjustment? That can unlock progress.

Every patient’s journey is different. Sometimes, it’s not about starting over—it’s about finding the dose that works.


💡 A Gentle Nudge, Not a Full Detour

This patient didn’t need a new medication or a brand-new protocol. He just needed someone to see the bigger picture and make a targeted change. That one adjustment helped him stay the course—and ultimately, heal.

___________________

**Comment**

I wonder how many would have stayed the course if they would have known this information?

Dosage matters, in fact, according to Dr. Burrascano, blood levels of various drugs were undetectable in some patients, despite using the same exact CDC guideline of 200 mg of doxycycline.

For more:

BTW: I felt miserable on antibiotics while my husband felt better.  Every person has their own response.  Treating this with an individual approach is imperative as no two respond identically.  This is why mainstream medicine is woefully unprepared and inexperienced in treating this.

Microbes & Mental Health Webinar Q & A

https://rawlsmd.com/webinars/microbesmentalhealth/?

Chronic Lyme Connection

Reserve My Seat

LIVE WEBINAR + Q&A

Let’s change the way we talk about Lyme and mental health—together.

Tuesday, May 27th, 4:00pm EDT

Have your questions ready for a LIVE Q&A with Dr. Bransfield & Dr. Rawls.

PLUS: Webinar attendees will have the opportunity to get Dr. Rawls’ bestselling book, Unlocking Lyme for free.

Reserve My Seat

JOIN US: Tuesday, May 27 4:00PM EDT
A Special Event for Lyme Awareness & Mental Health Awareness Month

Chronic Lyme Isn’t Just Physical.
It Affects the Mind, Too

If you’ve struggled with anxiety, depression, OCD, or cognitive challenges as part of your chronic Lyme experience, you’re not alone—and you’re not imagining it.

For too long, the emotional and neurological symptoms of chronic Lyme disease have gone unrecognized or misdiagnosed. But emerging science—and the lived experience of thousands—makes it clear: stealth microbes can impact the brain, nervous system, and mental health.

Join Us for a Groundbreaking Conversation

In this live event, two leading experts—Dr. Bill Rawls and Dr. Robert Bransfield—will explore the often-overlooked connection between chronic infections and mental health symptoms.

Together, they’ll unpack how microbes like borrelia and bartonella may contribute to mood changes, psychiatric conditions, and feelings of isolation—and what you can do to begin healing. You’ll learn:

How chronic Lyme and co-infections can influence brain function and mood
Why anxiety, OCD, and depression are common in Lyme patients

What a more complete approach to healing really looks lik

The role of stealth microbes in triggering neuroinflammation

Dr. Robert Bransfield

Neuropsychiatrist and internationally recognized expert on the psychiatric impacts of chronic infections. Known for pioneering work on how tick-borne illnesses influence mental health.

Meet the Experts:

Dr. Bill Rawls

Author of Unlocking Lyme and The Cellular Wellness Solution, Dr. Rawls is a physician, herbalist, and creator of RESTORE180™. He is a wellness educator who brings lived experience and integrative insight to chronic illness recovery.

Why This Conversation Matters

Mental health challenges are one of the most isolating aspects of chronic illness. They often get overlooked—by providers, by loved ones, even by ourselves.

This event is about validation, education, and community. Whether you’re living with chronic Lyme, supporting someone who is, or seeking better answers—you deserve to be part of this conversation.

Tuttle Destroys NASEM’s Report Part 2

https://www.change.org/p/the-us-senate-calling-for-a-congressional-investigation-of-the-cdc-idsa-and-aldf/

The IDSA’s Post Treatment Lyme Disease Syndrome was not good enough! (Part 2)

Carl Tuttle
Hudson, NH, United States
May 21, 2025

Please see the following response to my inquiry previously sent to Dr. Marcia McNutt regarding the National Academies Report “Lyme Infection-Associated Chronic Illnesses”

Original inquiry found here:

The IDSA’s Post Treatment Lyme Disease Syndrome was not good enough!

Response from the National Academies of Sciences:

———- Original Message ———-
From: “Liao, Julie” <JLiao@nas.edu>
To: CARL TUTTLE <runagain@comcast.net>
Date: 05/19/2025 9:47 AM EDT
Subject: Re: Inquiry on National Academies report, Charting a Path Toward New Treatments for Lyme Infection-Associated Chronic Illnesses

Good morning,

I am a senior program officer at the National Academies and co-director of the study that produced the report, Charting a Path Toward New Treatments for Lyme Infection-Associated Chronic Illnesses. Dr. McNutt shared your message with me, and I am responding on her behalf as a lead staff for the project.

First of all, thank you for your interest in this report and sharing these concerns. The National Academies committee that authored this report is aware of the painful history of disbelief and mistrust in the early days of recognizing and studying persistent symptoms associated with Lyme disease. It is their hope that this report takes the first step toward moving past this history to catalyze actions that prioritize discovery and development of new, effective, safe treatments for people living with these symptoms. To this end, the report explicitly recognizes that Lyme infection-associated chronic illnesses are real, and that these illnesses are debilitating to the health and well-being of many individuals.

Regarding the concern on funding development and use of new antimicrobials, the report recognizes that there may be a multitude of pathogenic mechanisms and calls for exploration of new treatments that can address the different potential pathways leading to these chronic symptoms. This includes pathogen persistence, as well as autoimmunity or other immune dysregulation as a result of Lyme disease.

It is the committee’s hope that new evidence will continue to emerge and advance our collective knowledge and ability to mitigate and one day cure these infection-associated chronic illnesses, including those associated with Lyme disease.

Warm regards,

Julie

Julie Liao, PhD (she/her)
Co-Director
Forum on Microbial Threats
Study on Evidence Base for Lyme-IACI Treatment
Keck 854 | (202) 334-2191

National Academies of Sciences, Engineering, and Medicine
500 Fifth Street, NW
Washington, DC 20001

nationalacademies.org/HMD

Carl Tuttle’s reply:

———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: “Liao, Julie” <JLiao@nas.edu>
Cc: “mmcnutt@nas.edu” <mmcnutt@nas.edu>, “vdzau@nas.edu” <vdzau@nas.edu>, “wkearney@nas.edu” <wkearney@nas.edu>, “dmay@nas.edu” <dmay@nas.edu>, “amacdonald@nas.edu” <amacdonald@nas.edu>
Date: 05/20/2025 10:02 AM EDT
Subject: Re: Inquiry on National Academies report, Charting a Path Toward New Treatments for Lyme Infection-Associated Chronic Illnesses

Dear Dr. Liao,

Thank you for responding to my inquiry sent to Dr. Marcia McNutt which is now in the public domain posted as an Update to the Change.org petition; Calling for a Congressional investigation of the CDC, IDSA and ALDF with 106,773 verified signatures.

The optimal treatment for Lyme disease has yet to be determined because the focus early on went directly into developing a vaccine. Here are some examples of how other difficult infections have been handled:

It was once believed that rifampin was curative in treating Brucellosis but when symptoms returned doxycycline was added to the mix and when that too failed a third antibiotic, streptomycin was added to the current treatment regimen. [1] [2]

In 1985 the worldwide incidence of leprosy was 6,000,000. Last year, it was 800,000. The only thing that changed was the addition of rifampin to dapsone in the treatment of the disease. Rifampin was added to dapsone because the M leprae were becoming resistant and it was a new antibiotic at that time.

Treatments for multidrug-resistant tuberculosis have been introduced (bedaquiline and delamanid) with more in the pipeline. [3]

A new treatment for recurrent Clostridium difficile was recently studied (bezlotoxumab) for reducing the risk of a repeat infection. [4]

In contrast, oral amoxicillin or doxycycline remains the treatment of choice for treating Lyme disease for over thirty years regardless if debilitating symptoms return. In 1977 Dr. Allen Steere knew that these antibiotics were not effective for all patients [5] but there has been no change in treatment or research to find more effective ways to eradicate the infection in all stages/forms of disease.

At what point in time do we recognize that we are dealing with an antibiotic resistant/tolerant superbug and focus our research on finding new antimicrobials for this life-altering/life-threatening disease as more of the population becomes severely disabled from inappropriately treated Lyme disease.

From your reply: The report recognizes that there may be a multitude of pathogenic mechanisms and calls for exploration of new treatments that can address the different potential pathways leading to these chronic symptoms. This includes pathogen persistence, as well as autoimmunity or other immune dysregulation as a result of Lyme disease.”

Those of us who have studied the mishandling of Lyme disease believe this is just lip service and the real effort will be spent on expensive treatments for the sick and disabled Lyme community still suffering from chronic Lyme; there’s more profit in providing a lifetime of drugs than on a cure and if a chronic relapsing seronegative disease were identified through the proposed “actions” it would end the current vaccine dream overnight because you cannot prove vaccine efficacy in a disease where we do not know who has or does not have the infection; having a curative approach would also give the public an excuse not to take their vaccine. (Let that sink in)

The Evidence is overwhelming that we have been dealing with an antibiotic resistant/tolerant superbug while the so-called science is (mis)used for legalized gaslighting (Follow the science) The IDSA/CDC have defined the disease (= high costs) away so when patients object; MD’s successfully hide behind their definition and guidelines.

I want to make this crystal clear: Suppressing evidence of antibiotic resistance (as well as ignoring these actions) is a crime and the National Academies has been given detailed notice of this atrocity.
 
Questions:

1. Will the search to find new antibiotics [6] be the research priority?

2. Who will be given responsibility for these studies? (certainly not the same researchers who previously received Lyme funding from the CDC/NIH)

A response to this inquiry is requested.

Carl Tuttle
Independent Researcher
Hudson, NH

Cc: Marcia McNutt, President of the National Academy of Sciences and Chair of the National Research Council
REFERENCES (PLEASE READ!)

1. Chronic Brucellosis and Persistence of Brucella melitensis DNA
https://www.ncbi.nlm.nih.gov/pubmed/?term=Chronic+Brucellosis+and+Persistence+of+Brucella+melitensis+DNA

After acute brucellosis infection, symptoms persist in a minority of patients for more than 1 year. Such patients are defined as having chronic brucellosis. Since no objective laboratory methods exist to confirm the presence of chronic disease, these patients suffer delays in both diagnosis and treatment.

2. Administration of a triple versus a standard double antimicrobial regimen for human brucellosis more efficiently eliminates bacterial DNA load.
https://www.ncbi.nlm.nih.gov/pubmed/25246401

The doxycycline-streptomycin-rifampin regimen eliminates Brucella DNA more efficiently than doxycycline-streptomycin, which may result in superior long-term clearance of Brucella.

3. Global Introduction of New Multidrug-Resistant Tuberculosis Drugs—Balancing Regulation with Urgent Patient Needs
https://wwwnc.cdc.gov/eid/article/22/3/15-1228_article

4. New C.diff treatment reduces recurrent infections by 40%
https://www.sciencedaily.com/releases/2017/01/170126081724.htm

5. Lyme arthritis: an epidemic of oligoarticular arthritis in children and adults in three connecticut communities. (1977)
Steere AC, Malawista SE, Snydman DR, Shope RE, Andiman WA, Ross MR, Steele FM.

Excerpt:

“The best treatment for this illness is not clear. Some physicians have reported that penicillin or tetracycline results in disappearance of the skin lesion (41,42), but others find antibiotics ineffective. Four of the patients with expanding skin lesions received penicillin but still developed arthritis.”

6. Lyme Disease: Call for a “Manhattan Project” to Combat the Epidemic
Raphael B. Stricker, Lorraine Johnson

Published: January 02, 2014

http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1003796

Carl Tuttle’s follow-up message:

———- Original Message ———-
From: CARL TUTTLE <runagain@comcast.net>
To: “Liao, Julie” <JLiao@nas.edu>
Cc: “mmcnutt@nas.edu” <mmcnutt@nas.edu>, “vdzau@nas.edu” <vdzau@nas.edu>, “wkearney@nas.edu” <wkearney@nas.edu>, “dmay@nas.edu” <dmay@nas.edu>, “amacdonald@nas.edu” <amacdonald@nas.edu>
Date: 05/21/2025 8:42 AM EDT
Subject: Re: Inquiry on National Academies report, Charting a Path Toward New Treatments for Lyme Infection-Associated Chronic Illnesses

Dr. Liao,

It’s no surprise that the Chair of your committee that published the Consensus Study Report is a vaccinologist. This validates everything I have been reporting about the rush to create a vaccine for Lyme which led to the deliberate mishandling of the disease.

It is obvious that the priority here is still the Lyme vaccine and finding a cure for chronic Lyme is just lip service.

THE GENEVA FOUNDATION

CHAIR OF THE BOARD OF DIRECTORS
 
KENT KESTER, MD, COL (RET.), USA

https://genevausa.org/about/leadership-in-military-medicine/board-of-directors/col-ret-kent-kester/

Kent E. Kester, M.D., is currently Executive Director
Vaccine Research and Development at the Coalition
for Epidemic Preparedness Innovations (CEPI)

Carl Tuttle

_______________

Part 1 here: https://madisonarealymesupportgroup.com/2025/05/16/tuttle-destroys-nasems-lyme-disease-report/

I posted the NASEM Report – ‘new treatments for Lyme Infection-Associated Chronic Illnesses’ here:  https://madisonarealymesupportgroup.com/2025/05/09/charting-a-path-towards-new-treatments-for-chronic-lyme-disease/

Again, here is the old 2014 interview with Willy Burgdorfer where he states research must be started over at square one because the same people have been doing the research and coming up with the same results – nothing!

http:// Approx. 5 Min

Willy Burgdorfer 2014

“Money goes to people that have for the past 30 years produced the same thing.  Nothing.” ~  Willy Burgdorfer

Well, it’s now been a total of more than 40 years and the same thing is being produced, which is nothing.

Yeah – I agree.  Total lip-service to patients. 

It’s all about the ‘vaccine.’

How Are MS & Chronic Lyme Related?

Although this article is about MS, I wanted to post this information from Dr. Makis on fibromyalgia since both have many similar symptoms:  https://makismd.substack.com/p/ivermectin-and-fibromyalgia-testimonials?

In short, fibromyalgia patients are experiencing great relief, and even cure with ivermectin.  Many are stating their pain is entirely or nearly gone.  A few MS patients claim ivermectin cured their MS.

https://www.lymedisease.org/multiple-sclerosis-chronic-lyme/

How are multiple sclerosis and chronic Lyme related?

By Bill Rawls, MD

April 21, 2025

Multiple sclerosis (MS) is a disease where the immune system attacks the protective covering (called myelin) around nerves in the brain and spinal cord.

Myelin acts like an insulator to keep nerves from touching each other and shorting out, much like the plastic coating on a copper wire.

This damage disrupts nerve signals, leading to symptoms such as fatigue, muscle weakness, numbness, vision problems, and coordination difficulties.

Undoubtedly, plenty of people who identify as having chronic Lyme disease struggle with these same symptoms. And demyelination of nerves has been documented for Lyme disease. Beyond that, many people with MS test positive for Borrelia, the Lyme bacteria. So what distinguishes MS from chronic Lyme?

The answer: arbitrary cut-offs.

So how do we differentiate?

There is no single test that is specific for MS. The diagnosis of MS is made using a combination of clinical evaluation, imaging, such as MRI, and laboratory tests of blood and spinal fluid.

If all of the findings are deemed significant enough by the clinician evaluating the patient, then the diagnosis of MS is made and the patient qualifies for treatment.

This means that a person could have all of the symptoms, and some or all of the findings, but not to the degree that would qualify for a diagnosis of MS.

That person might end up being diagnosed with some other neurological condition, fibromyalgia, or maybe wouldn’t get a diagnosis at all. Chronic Lyme disease is unlikely because it isn’t a diagnosis recognized by the conventional medical community.

No diagnosis, no treatment. But maybe that’s not such a bad thing.

Getting to the root cause

There are numerous drugs for treatment of MS. They work by blocking inflammation or blocking the immune system’s assault on myelin. The benefits are marginal at best and they carry significant side effects.

What the drugs don’t do is address why the body is attacking myelin in the first place. Without getting to the root causes of the problem, patients typically don’t get well. They live in a compromised state of relying on medications to mask the symptoms of their illness.

When you start looking for underlying causes, you’ll find that MS is listed as multifactorial. In other words, it’s not one specific cause, but rather multiple variable causes. This is also true of other chronic illnesses, including chronic Lyme disease.

A review paper published in the 2023 edition of the journal, NeuroSci, cataloged some of the known risk factors for MS that may be causative. These risk factors can be grouped into five categories.

  • Diets rich in processed foods and saturated fat, but low in vegetables and fruit
  • Chronic mental stress with inadequate sleep
  • Smoking or chronic exposure to other toxic substances
  • Sedentary lifestyle
  • Certain myelin-scavenging microbes, including (but not limited to) Chlamydia pneumoniae, Epstein-Barr Virus (EBV), Human Herpesvirus-6 (HHV-6), Mycoplasma pneumoniae and other mycoplasma species, and Borrelia burgdorferi

While the review didn’t go as far as defining how these factors might come together to cause MS, it doesn’t take much imagination to figure out a possible scenario.

A plausible explanation for MS

Myelin is contained within specialized cells called oligodendrocytes, which wrap around the shaft of a nerve to insulate it. Each of these microbes are known to invade oligodendrocytes to scavenge myelin as a resource for replication. While this provides one possible link to MS, that’s not the end of the story.

Evidence shows that the microbes can go dormant inside an oligodendrocyte after they invade it. Intracellular dormancy is a common survival mechanism used by many host-dependent microbes. It has been documented for borrelia and all the Lyme coinfections. Dormancy allows microbes to survive when conditions aren’t favorable for growth — in other words, when the cells they’ve invaded are healthy.

When cells are weakened by chronic stress factors — poor diet, chronic exposure to toxic substances, unrelenting mental stress and poor sleep, being sedentary — dormant microbes are able to reactivate, consume the cell, and then emerge to infect adjacent cells.

The immune system reacts by attacking the oligodendrocytes where microbes are emerging, in the process compounding the damage.

This is also a plausible explanation for chronic Lyme disease. The question remains: Why do some people progress to more advanced symptoms that are ultimately defined as MS?

The answer may be genetics. A variety of genetic mutations are common among people diagnosed with MS. You can’t do anything about genetic mutations, of course, but you can do something about the root causes of the problem.

A natural solution for MS and chronic Lyme

One obvious part of the solution is minimizing stress factors that weaken cells. Not surprisingly, there are many documented cases of people who went into stable remission from MS after modifying their health habits.

Improved health habits alone, however, don’t completely address the microbe factor. Fortunately, there is one thing that does — and it’s not antibiotics or other drugs.

Certain medicinal herbs demonstrate antimicrobial and immunomodulating properties that offer the potential for an ideal solution to support recovery from MS. They are already used widely for chronic Lyme disease and supported by sound evidence.

Among numerous studies, a study from Johns Hopkins University showed that certain herbs — cryptolepis, Japanese knotweed, and Chinese skullcap — were more effective for killing Borrelia than antibiotics.

Unlike an antibiotic, however, which is a single chemical agent specific for only certain microbes, an herb contains hundreds of chemical substances that act as a chemical defense system against a wide range of microbes, including bacteria, viruses, protozoa, and yeasts.

Never just one

This is important because it’s never just one microbe possibility. People identifying as having chronic Lyme disease typically test positive for co-infections. Chronic Lyme co-infections associated with demyelination include Chlamydia pneumoniaeEpstein-Barr Virus (EBV), Human Herpesvirus-6 (HHV-6), Mycoplasma pneumoniae and other mycoplasma species.

But these are just the ones that have been identified so far — there are probably many others.

Combining multiple herbs extends the range of coverage. This is possible because the potential for toxicity of the most commonly used herbs in Lyme protocols is inherently low.

Medicinal herbs and mushrooms that are commonly included in chronic Lyme protocols that could also be beneficial for MS recovery include:

  • Japanese knotweed (Polygonum cuspidatum)
  • Cat’s claw (Uncaria tomentosa)
  • Chinese skullcap (Scutellaria baicalensis).
  • Cryptolepis (Cryptolepis sanguinolenta)
  • Andrographis (Andrographis paniculata)
  • Reishi (Ganoderma lucidum)
  • Cordyceps (Cordyceps sinensis)
  • Berberine or berberine-containing herbs
  • Red sage (Salvia miltiorrhiza)
  • Rehmannia (Rehmannia glutinosa)

Very importantly, the complex chemistry of herbs and medicinal mushrooms also protects cells from a wide range of toxic threats, including free radicals, foreign toxic substances, and harmful radiation. This applies to all cells in the body, including cells that make up the nervous system.

Immunomodulators

The medicinal herbs and mushrooms listed are classified as immunomodulators, meaning they upregulate underactive parts of the immune system and downregulate overactive portions of the immune system. This is important for reducing inflammation and calming the autoimmune response.

A final advantage of antimicrobial herbs is specificity for pathogens. The antimicrobial properties of herbs and medicinal mushrooms are selective for pathogens, but do not disrupt normal flora in the gut and other areas of the body.

Low toxicity and low potential to disrupt the gut microbiome means that herbal therapy can be used for extended durations, months or even years, which is often what it takes for complete recovery.

What this all means is that therapy — with a targeted endpoint of wellness, not managed illness — can be started with or without having a formal diagnosis.

With over 30 years of medical experience, Dr. Bill Rawls specializes in the holistic treatment of chronic illnesses, particularly Lyme disease. His personal journey with Lyme disease inspired his mission to empower others with the knowledge and tools needed to regain their health naturally. Learn more about Dr. Rawls’ approach to treating chronic illness with herbal therapy at RawlsMD.com.

References

An X, Bao Q, Di S, et al. The interaction between the gut microbiota and herbal medicines. Biomed Pharmacother. 2019;118:109252.

Anderson C, Brissette CA. The Brilliance of Borrelia: Mechanisms of Host Immune Evasion by Lyme Disease-Causing Spirochetes. Pathogens. 2021;10(3):281.

Berer K, Mues M, Koutrolos M, et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature. 2011;479(7374):538-541.

Bjornevik K, Münz C, Cohen JI, Ascherio A. Epstein-Barr virus as a leading cause of multiple sclerosis: mechanisms and implications. Nat Rev Neurol. 2023;19(3):160-171.

Branton WG, Lu JQ, Surette MG, et al. Brain microbiota disruption within inflammatory demyelinating lesions in multiple sclerosis. Sci Rep. 2016;6:37344.

Eisenreich W, Rudel T, Heesemann J, Goebel W. Persistence of Intracellular Bacterial Pathogens-With a Focus on the Metabolic Perspective. Front Cell Infect Microbiol.

Feng J, Leone J, Schweig S, Zhang Y. Evaluation of Natural and Botanical Medicines for Activity Against Growing and Non-growing Forms of B. burgdorferiFront Med (Lausanne). 2020;7:6.

Fritzsche M. Chronic Lyme borreliosis at the root of multiple sclerosis–is a cure with antibiotics attainable? Med Hypotheses. 2005;64(3):438-448.

Greening C, Grinter R, Chiri E. Uncovering the Metabolic Strategies of the Dormant Microbial Majority: towards Integrative Approaches. mSystems. 2019;4(3):e00107-19.

Ivanova MV, Kolkova NI, Morgunova EY, et al. Role of Chlamydia in multiple sclerosis. Bull Exp Biol Med. 2015;159(5):646-648.

Kriesel JD, et al. Spectrum of Microbial Sequences and a Bacterial Cell Wall Antigen in Primary Demyelination Brain Specimens Obtained from Living Patients. Sci Rep. 2019 Feb 4;9(1):1387.

Landry RL, Embers ME. The Probable Infectious Origin of Multiple Sclerosis. NeuroSci. 2023;4(3):211-234.

Libbey JE, Cusick MF, Fujinami RS. Role of pathogens in multiple sclerosis. Int Rev Immunol. 2014;33(4):266-283.

Livengood JA, Gilmore RD Jr. Invasion of human neuronal and glial cells by an infectious strain of Borrelia burgdorferi [published correction appears in Microbes Infect. 2015 Jun;17(6):e1]. Microbes Infect. 2006;8(14-15):2832-2840.

Pender M. The essential role of Epstein-Barr virus in the pathogenesis of multiple sclerosis. Neuroscientist. 2011;17(4):351-367.

Rittershaus ES, Baek SH, Sassetti CM. The normalcy of dormancy: common themes in microbial quiescence. Cell Host Microbe. 2013;13(6):643-651.

Thakur A, Mikkelsen H, Jungersen G. Intracellular Pathogens: Host Immunity and Microbial Persistence Strategies. J Immunol Res. 2019;2019:1356540.

Toledo A, Benach JL. Hijacking and Use of Host Lipids by Intracellular Pathogens. Microbiol Spectr. 2015;3(6):10.1128/microbiolspec.VMBF-0001-2014.

_______________

**Comment**

A few points:

  • The Johns Hopkins study was in vitro, or the lab, which may not transfer over to the human body.
  • Antibiotics of daptomycin, doxycycline, and cefuroxime were used as controls at a final concentration of 5 μg/ml.  I’m not sure how this translates to oral dosages given patients, but according to Burrascano, dosages matter greatly.  It could be that these dosages were not high enough.
  • Doxy is a great front-line drug due to its action against many coinfections, but it is not the best and only drug to treat Lyme disease.
    • Eva Sapi found that while the use of doxy reduced spirochetal structures ~90%, round body forms increased about twofold.What this means is these round forms will simply lie and wait until conditions are better to reemerge. She found that tinidazole was the only antibiotic that reduced viable organisms by ~90%.  Recent research showed piperacillin effectively cured mice of Lyme at a dose 100 times smaller than doxycycline with virtually no impact on resident gut microbes.
So, for anyone paying attention, doxy has its limitations and all experienced Lyme literate doctors use multiple antibiotics in a combination therapy.

This, right here, is why mainstream medicine and research are worthless because this complex illness is treated as a one pathogen, one drug illness when typically more than one pathogen involved, and to complicate it further, the pathogens have multiple forms (pleomorphism) and strains that need to be addressed.

  • Daptomycin is an antibiotic that has been utilized recently in combination therapies. In a study through Johns Hopkins, when combined with doxycycline and ceftriaxone, daptomycin effectively cleared Lyme disease infection in vitro as well as in mice. However, daptomycin is relatively expensive and only available intravenously.  Notice it’s effectiveness is due to being used in a combo therapy.  I would say this is true of ALL antibiotics and why single antibiotics were not successful in the Johns Hopkins study Rawls refers to.
  • While cefuroxime has been found to have a minimum bactericidal concentration (MBC) similar to doxycycline; out of three borrelia species tested, two were susceptible while the third (borrelia hermsii) was less susceptible. The three antibiotics with similar MBCs in vitro, i.e., cefuroxime, doxycycline, and amoxicillin, demonstrated comparable activities in preventing borreliosis in B. burgdorferi-challenged hamsters (50% curative doses = 28.6, 36.5 and 45.0 mg/kg, respectively). So cefuroxime is far from perfect either when used alone.  Source

Using single antibiotics is really doing an injustice to what is known about successful treatment for Lyme since tindy is the most effective drug overall and combination drug protocols are by far the most effective.

Please remember too that Dr. Rawls manufactures and sells herbs and is financially compensated.

Don’t misunderstand – I’m not opposed to herbs.  I’ve used many myself and know of patients who have done well on them.  I just don’t want you to believe they are perfect or the only answer, either.  It takes everything AND the kitchen sink for this crap so keep an open mind.  And herbs are not harmless – there are interactions with other drugs as well as toxicity.

Nothing is ever simple.

For more:

Why Doctor Treated Patient for Lyme – Even When His Test Was Negative

https://danielcameronmd.com/treated-lyme-negative-test/

Why I Treated Him for Lyme—Even When His Test Was Negative

May 13, 2025

Patients Deserve an Explanation

One of the most common—and most important—questions I hear from patients is:
“If my Lyme test is negative, why are you still treating me?”

It’s a fair question. And if you’re asking it, you deserve a clear and compassionate answer. The truth is, when it comes to Lyme disease, test results don’t always tell the full story.

Let’s break down why.


Lyme Disease Testing Isn’t Always Reliable

The standard test used to diagnose Lyme disease is called the two-tier system. It includes an ELISA screening test followed by a Western blot if the first result is positive. But this system is far from perfect—especially when the infection is in its early or late stages.

Here’s what you should know:

  • Early in the infection, your body may not have produced enough antibodies yet to trigger a positive result
  • Some patients never produce detectable antibodies at all
  • Co-infections like Babesia or Bartonella are not picked up by this test
  • Many rashes don’t appear in the textbook “bulls-eye” pattern—or don’t appear at all
So yes—you can absolutely have Lyme disease, even if your test is negative. And unfortunately, this is more common than many realize.

In Medicine, We Don’t Wait for Disease to Get Worse

In most areas of healthcare, we don’t wait for a serious event before we start treatment.

  • We don’t wait for a stroke to treat high blood pressure
  • We don’t wait for vision loss to manage diabetes
  • We don’t wait for full organ failure to address chronic kidney disease

We act early—because we know that early treatment improves outcomes. So why does Lyme disease often get treated differently?

When it comes to Lyme, many patients are told to “wait and see”—even when the symptoms are clear and distressing.

Waiting Is Not a Neutral Decision

Here’s what I tell my patients:
Waiting is not harmless. It’s a medical decision with consequences.

Delaying treatment can allow symptoms to worsen. It can allow the infection to persist or spread. In some cases, patients who were told to wait eventually end up with a label: Post-Treatment Lyme Disease Syndrome (PTLDS)—a condition where symptoms linger long after the initial infection was treated, or in some cases, never properly treated at all.

What if we had treated earlier? Could we have prevented months—or even years—of suffering?

In many cases, the answer is yes.


Clinical Judgment Is Not Guesswork

When I decide to treat someone for Lyme disease despite a negative test, it’s not a random decision. It’s based on:

• The full pattern of your symptoms

• Your medical history

• Your response to prior treatments

• Known or likely tick exposure

• And experience with thousands of Lyme patients

This is called clinical judgment. It’s a core part of good medical practice. I don’t ignore science—I apply it in context. Because Lyme doesn’t always follow the rules, and neither should we when those rules are failing real people.


You Know When Something Feels Wrong

I’ve met patients who’ve been told their symptoms are “just stress” or “hormonal” or “all in their head.” But they know their bodies. They’ve tracked their fatigue, their joint pain, their cognitive changes. They’ve seen something shift—and they’re right to speak up about it.

Many of those patients improve once treatment begins, even if their test results never confirmed the diagnosis. That’s not luck. That’s Lyme disease showing up in real life—even when it doesn’t show up in the lab.


It’s Time to Rethink How We Treat Lyme

We’re in a new era of medicine. Patients are more informed, more proactive, and more in tune with their own health than ever before. But too often, our Lyme diagnostic standards are stuck in the past—waiting for certainty while people lose months or years of their lives to untreated illness.

We need to bring clinical judgment back into focus. We need to listen more, wait less, and treat Lyme disease with the urgency it deserves.


Final Thoughts

If you’ve been told your test is negative, but you’re still struggling with symptoms—please know this:
You’re not imagining it. You’re not overreacting. And you’re not alone.

In my practice, I treat the whole patient—not just the lab result. Because when it comes to Lyme, early treatment can change everything.


Want to learn more? Follow my blog series for more insights on Lyme disease diagnosis and care—or reach out to my office if you’re looking for answers.
You deserve to be heard.

Related Articles:

Relying on a negative Lyme disease test can prove deadly

Don’t wait for a positive Lyme disease test

Can’t trust single dose of doxycycline to prevent Lyme disease

_______________

**Comment**

A very needed article with crucial information for all to understand.

Testing for Lyme/MSIDS is abysmal Clinical judgement is required; however, doctors receive little training for tick-borne infections and whatever training they do receive is antiquated and biased.  The fact the needle hasn’t budged in 40 years is proof of this fact.

Dr. Cameron is an example of an independent doctor who could save your life.  He’s also a Lyme-literate doctor who has studied under ILADS and who has years of experience treating this.  Like many of his colleagues, he’s been attacked by the state medical board – which is common for these doctors because they do not partake in the globalist idea for ‘consensus-based’ medicine – which turns doctors into robots who blindly follow dictates from bureaucrats who are profiting from conflicts of interests including patents, drugs, and other metabolomics. 

Due to the horrific lack of education on all things Lyme/MSIDS, there is a parallel group to the tyrannical IDSA (Infectious Diseases Society of America) called ILADS (International Lyme and Associated Diseases Society) which holds their own medical conferences to educate doctors on what is happening in reality with Lyme/MSIDS and through independent, global research that the IDSA simply ignores or maligns. Their next conference, “The Complexity of Lyme: Diagnosing and Treating Tick-Borne and Related Diseases,” is June 7-8 in Philadelphia.

Our conference will include:

  • Introduction to diagnosing and treating vector-borne diseases
  • Case discussions with experts
  • Advanced topics in clinical treatments such as PANS/PANDAS, Mold toxicity, MCAS, supportive natural therapies and more.
  • Exhibitors showcasing medical services
  • CME credit available

The conference is open to healthcare professionals. Students enrolled in a medical degree program and PhD candidates conducting Lyme-related research are also eligible to attend and qualify for discounted rates. Email conference@ilads.org for more information.